212 related articles for article (PubMed ID: 8395870)
1. DNA topoisomerase I and II as targets for rational design of new anticancer drugs.
Cummings J; Smyth JF
Ann Oncol; 1993 Aug; 4(7):533-43. PubMed ID: 8395870
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
3. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
4. Salvicine, a novel DNA topoisomerase II inhibitor, exerting its effects by trapping enzyme-DNA cleavage complexes.
Meng LH; Zhang JS; Ding J
Biochem Pharmacol; 2001 Sep; 62(6):733-41. PubMed ID: 11551518
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic evidence that DNA topoisomerase II is not involved in radiation induced chromsome-type aberrations.
Mosesso P; Pepe G; Ottavianelli A; Schinoppi A; Cinelli S
Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():14-8. PubMed ID: 26520368
[TBL] [Abstract][Full Text] [Related]
6. Human DNA-Topoisomerases - Diagnostic and Therapeutic Implications for Cancer.
Kellner U; Rudolph P; Parwaresch R
Onkologie; 2000 Oct; 23(5):424-430. PubMed ID: 11441236
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase II enzymes and mutagenicity.
Ferguson LR; Baguley BC
Environ Mol Mutagen; 1994; 24(4):245-61. PubMed ID: 7851337
[TBL] [Abstract][Full Text] [Related]
8. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
Prost S; Riou G
Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
[TBL] [Abstract][Full Text] [Related]
9. Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II-mediated DNA cleavage by gossypol.
Adlakha RC; Ashorn CL; Chan D; Zwelling LA
Cancer Res; 1989 Apr; 49(8):2052-8. PubMed ID: 2539251
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase II inhibitors fail to induce chromosome-type aberrations in etoposide-resistant cells: evidence for essential contribution of the cleavable complex formation to the induction of chromosome-type aberrations.
Suzuki H; Tarumoto Y; Ohsawa M
Mutagenesis; 1997 Jan; 12(1):29-33. PubMed ID: 9025094
[TBL] [Abstract][Full Text] [Related]
12. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Christmann M; Tomicic MT; Gestrich C; Roos WP; Bohr VA; Kaina B
DNA Repair (Amst); 2008 Dec; 7(12):1999-2009. PubMed ID: 18805512
[TBL] [Abstract][Full Text] [Related]
13. An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells.
Padget K; Stewart A; Charlton P; Tilby MJ; Austin CA
Biochem Pharmacol; 2000 Sep; 60(6):817-21. PubMed ID: 10930536
[TBL] [Abstract][Full Text] [Related]
14. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
15. Molecular interactions of DNA-topoisomerase I and II inhibitor with DNA and topoisomerases and in ternary complexes: binding modes and biological effects for intoplicine derivatives.
Nabiev I; Chourpa I; Riou JF; Nguyen CH; Lavelle F; Manfait M
Biochemistry; 1994 Aug; 33(30):9013-23. PubMed ID: 8043587
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
17. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
Feldhoff PW; Mirski SE; Cole SP; Sullivan DM
Cancer Res; 1994 Feb; 54(3):756-62. PubMed ID: 8306338
[TBL] [Abstract][Full Text] [Related]
18. Immunodetection of human topoisomerase I-DNA covalent complexes.
Patel AG; Flatten KS; Peterson KL; Beito TG; Schneider PA; Perkins AL; Harki DA; Kaufmann SH
Nucleic Acids Res; 2016 Apr; 44(6):2816-26. PubMed ID: 26917015
[TBL] [Abstract][Full Text] [Related]
19. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
20. The function of DNA topoisomerases in UV-induced DNA excision repair: studies with specific inhibitors in permeabilized human fibroblasts.
Popanda O; Thielmann HW
Carcinogenesis; 1992 Dec; 13(12):2321-8. PubMed ID: 1335377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
